128 related articles for article (PubMed ID: 34531827)
1. Corrigendum: High Circulating Follicle-Stimulating Hormone Level Is a Potential Risk Factor for Renal Dysfunction in Post-Menopausal Women.
Li Q; Zheng D; Lin H; Zhong F; Liu J; Wu Y; Wang Z; Guan Q; Zhao M; Gao L; Zhao J
Front Endocrinol (Lausanne); 2021; 12():710836. PubMed ID: 34531827
[TBL] [Abstract][Full Text] [Related]
2. High Circulating Follicle-Stimulating Hormone Level Is a Potential Risk Factor for Renal Dysfunction in Post-Menopausal Women.
Li Q; Zheng D; Lin H; Zhong F; Liu J; Wu Y; Wang Z; Guan Q; Zhao M; Gao L; Zhao J
Front Endocrinol (Lausanne); 2021; 12():627903. PubMed ID: 33868168
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum: High follicle-stimulating hormone level associated with risk of rheumatoid arthritis and disease activity.
Zhang X; Qiao P; Guo Q; Liang Z; Pan J; Wu F; Wang X; Zhang L
Front Endocrinol (Lausanne); 2023; 14():1238584. PubMed ID: 37424862
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic role of follicle-stimulating hormone (FSH) measurements during the menopausal transition--an analysis of FSH, oestradiol and inhibin.
Burger HG
Eur J Endocrinol; 1994 Jan; 130(1):38-42. PubMed ID: 8124478
[TBL] [Abstract][Full Text] [Related]
5. Influence of low dose oestrogen on circulating prolactin. LH and FSH levels in post-menopausal women.
Robyn C; Vekemans M
Acta Endocrinol (Copenh); 1976 Sep; 83(1):9-14. PubMed ID: 989226
[TBL] [Abstract][Full Text] [Related]
6. Follicle-stimulating hormone promotes renal tubulointerstitial fibrosis in aging women via the AKT/GSK-3β/β-catenin pathway.
Zhang K; Kuang L; Xia F; Chen Y; Zhang W; Zhai H; Wang C; Wang N; Lu Y
Aging Cell; 2019 Oct; 18(5):e12997. PubMed ID: 31243899
[TBL] [Abstract][Full Text] [Related]
7. Serum Follicle-Stimulating Hormone Levels Are Associated with Cardiometabolic Risk Factors in Post-Menopausal Korean Women.
Jung ES; Choi EK; Park BH; Chae SW
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32325717
[No Abstract] [Full Text] [Related]
8. Cycle and hormone changes during perimenopause: the key role of ovarian function.
Burger HG; Hale GE; Dennerstein L; Robertson DM
Menopause; 2008; 15(4 Pt 1):603-12. PubMed ID: 18574431
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of oestrogens, progesterone, follicle-stimulating hormone and sex-hormone-binding globulin during simultaneous vaginal administration of 17 beta-oestradiol and progesterone in the pre- and post-menopause.
Carlström K; Pschera H; Lunell NO
Maturitas; 1988 Dec; 10(4):307-16. PubMed ID: 3147360
[TBL] [Abstract][Full Text] [Related]
10. Changes in hypophysio-ovarian endocrinological function of post-menopausal and castrated women.
Furuhashi N; Abe T; Suzuki M; Yamaya Y; Takahashi K
Tohoku J Exp Med; 1976 Sep; 120(1):19-24. PubMed ID: 960105
[TBL] [Abstract][Full Text] [Related]
11. [The severity of menopausal symptoms and cardiovascular risk in women].
Isaeva AS; Vovchenko MN
Georgian Med News; 2014 Jun; (231):21-6. PubMed ID: 25020165
[TBL] [Abstract][Full Text] [Related]
12. Symptomatology and hormone profile of menopausal Nigerians.
Akingbade OA; Bolarinwa AF; Subbarao VV
Afr J Med Med Sci; 1990 Jun; 19(2):133-7. PubMed ID: 2115729
[TBL] [Abstract][Full Text] [Related]
13. Laboratory criteria for menopause in women using oral contraceptives.
Creinin MD
Fertil Steril; 1996 Jul; 66(1):101-4. PubMed ID: 8752618
[TBL] [Abstract][Full Text] [Related]
14. Pituitary dysfunction in recently post-menopausal women. Nottingham EPIC Study Group.
Lyons A; Ng C; Fielding K; Hosking D; Selby C; Lawson N
Clin Endocrinol (Oxf); 1997 Oct; 47(4):431-8. PubMed ID: 9404441
[TBL] [Abstract][Full Text] [Related]
15. Serum follicle-stimulating hormone and luteinizing hormone levels in women aged 35-60 in the U.S. population: the Third National Health and Nutrition Examination Survey (NHANES III, 1988-1994).
Backer LC; Rubin CS; Marcus M; Kieszak SM; Schober SE
Menopause; 1999; 6(1):29-35. PubMed ID: 10100177
[TBL] [Abstract][Full Text] [Related]
16. Do estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women.
Pae CU; Mandelli L; Han C; Ham BJ; Masand PS; Patkar AA; Steffens DC; De Ronchi D; Serretti A
Neuro Endocrinol Lett; 2008 Aug; 29(4):500-6. PubMed ID: 18766158
[TBL] [Abstract][Full Text] [Related]
17. Extragonadal Effects of Follicle-Stimulating Hormone on Osteoporosis and Cardiovascular Disease in Women during Menopausal Transition.
Zhu D; Li X; Macrae VE; Simoncini T; Fu X
Trends Endocrinol Metab; 2018 Aug; 29(8):571-580. PubMed ID: 29983231
[TBL] [Abstract][Full Text] [Related]
18. Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer.
Pujol P; Daurès JP; Brouillet JP; Maudelonde T; Rochefort H; Grenier J
Br J Cancer; 1999 Feb; 79(5-6):909-14. PubMed ID: 10070889
[TBL] [Abstract][Full Text] [Related]
19. 17 beta-oestradiol counteracts the formation of the more acidic isoforms of follicle-stimulating hormone and luteinizing hormone after menopause.
Wide L; Naessén T
Clin Endocrinol (Oxf); 1994 Jun; 40(6):783-9. PubMed ID: 8033370
[TBL] [Abstract][Full Text] [Related]
20. An investigation into the climacteric in Nigerians.
Aina AO
J Med Assoc Thai; 1992 Mar; 75(3):168-72. PubMed ID: 1506795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
